Virulence, immunogenicity and reactivation of bovine herpesvirus 1 mutants with a deletion in the gC, gG, gI, gE, or in both the gI and gE gene.
Within the framework of developing a marker vaccine against bovine herpesvirus 1 (BHV1), several mutants with deletions in non-essential glycoprotein genes were constructed. Glycoprotein gC, gG, gI and gE single deletion mutants, a gI/gE double deletion mutant and a gE frame-shift mutant were made. The virulence and immunogenicity of these mutants were evaluated in specific-pathogen-free calves. Except for the gC deletion mutant, all mutants were significantly less virulent than the parental wild-type (wt) BHV1 strain Lam. The virulence of the gI and the gI-/gE- mutants was almost completely reduced. Upon challenge infection, the calves of the control group became severely ill, whereas all other calves remained healthy. The reduction of the virus shedding after challenge infection was related to the virulence of the strain of primary inoculation. Virus shedding was almost completely reduced in calves first inoculated with Lam-wt or with gC- and the least reduced in calves inoculated with gI- or gI-/gE-. Six weeks after challenge, all calves were treated with dexamethasone to study whether mutant or challenge virus or both could be reactivated. The gC- and the gG- mutants were reactivated, whereas none of the other mutants were reisolated. Reactivation of challenge virus was reduced in all calves inoculated with mutant viruses. The gC deletion mutant was too virulent and the gI and the gI/gE deletion mutants were the least immunogenic, but based on residual virulence and immunogenicity, both the gG and the gE deletion mutants are candidates for incorporation in live BHV1 vaccines. However, it also depends on the kinetics of the anti-gG and anti-gE antibody response after wild-type virus infection, whether these deletion mutants are really suitable to be incorporated in a marker vaccine.
Kaashoek
M J
MJ
Department of Mammalian Virology, DLO-Institute for Animal Science and Health (ID-DLO), Lelystad, The Netherlands.
Rijsewijk
F A
FA
Ruuls
R C
RC
Keil
G M
GM
Thiry
E
E
Pastoret
P P
PP
Van Oirschot
J T
JT
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D003907:Dexamethasone / Q000627:therapeutic use; D005814:Genes, Viral; D006566:Herpesviridae Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D007242:Herpesvirus 1, Bovine / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity / Q000502:physiology*; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D017384:Sequence Deletion; D013047:Specific Pathogen-Free Organisms; D014764:Viral Proteins / Q000235:genetics* / Q000276:immunology / Q000502:physiology*; D015678:Viral Structural Proteins / Q000235:genetics*; D014765:Viral Vaccines / Q000276:immunology*; D014774:Virulence; D014775:Virus Activation
D000893:Anti-Inflammatory Agents; D000914:Antibodies, Viral; D014764:Viral Proteins; D015678:Viral Structural Proteins; D014765:Viral Vaccines; C046998:bovine herpesvirus type-1 glycoproteins; D003907:Dexamethasone